Effect of SGLT-2 inhibitors on the incidence of right ventricular dysfunction in patients with chronic heart failure

11 May 2026 (08:30 - 09:30)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Giandomenico Severini

Renato Dulbecco University Hospital of Catanzaro, Catanzaro (Italy)

8 More presentations in this session

Presentation thumbnail

Tafamidis for the treatment of wild-type transthyretin cardiac amyloidosis: insights from a regional hospital experience

Doctor A. Martins (Leiria, PT)

Abstract Slides

Presentation thumbnail

Transitions in heart failure therapy prior to acoramidis use in transthyretin cardiomyopathy: real world insights from the german starttr cohort

Doctor C. Morbach (Wuerzburg, DE)

Abstract Slides

Presentation thumbnail

Early realworld use of acoramidis insights from the german starTTR cohort

Doctor C. Morbach (Wuerzburg, DE)

Abstract Slides

Presentation thumbnail

Digoxin use and heart failure hospitalization in patients with heart failure with preserved ejection fraction: a real-world retrospective analysis

Associate Professor B. MURAT (Eskisehir, TR)

Abstract Slides

Presentation thumbnail

Effect of vericiguat on echodynamics and myocardial remodeling in patients with heart failure with reduced ejection fraction

Doctor C. Carbonaro (Turin, IT)

Abstract Slides

Access the full session

Session thumbnail

ePosters in chronic heart failure - pharmacotherapy (2)

The Event

Event poster

Heart Failure 2026

11 May 2026 08:30 CET

You may be interested in

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

Webinar

MRAs in heart failure: what's old is new again

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources